TISIDB

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Chromosome, centromere, kinetochore. Cytoplasm, cytoskeleton, spindle. Cleavage furrow. Note=Localizes to the interphase and S phase centrosome. During mitosis, partially associated with the mitotic spindle. Concentrates at the plus ends of microtubules coincident with kinetochores in metaphase and anaphase in a CENPF-dependent manner. Also localizes to the cleavage furrow during cytokinesis. manner. Also localizes to the cleavage furrow during cytokinesis.
Domain	PF04880 NUDE protein
Function	Required for centrosome duplication and formation and function of the mitotic spindle. Essential for the development of the cerebral cortex. May regulate the production of neurons by controlling the orientation of the mitotic spindle during division of cortical neuronal progenitors of the proliferative ventricular zone of the brain. Orientation of the division plane perpendicular to the layers of the cortex gives rise to two proliferative neuronal progenitors whereas parallel orientation of the division plane yields one proliferative neuronal progenitor and a post-mitotic neuron. A premature shift towards a neuronal fate within the progenitor population may result in an overall reduction in the final number of neurons and an increase in the number of neurons in the deeper layers of the cortex.

> Gene Ontology [ TOP ]
Biological Process	GO:0000086 G2/M transition of mitotic cell cycle GO:0000132 establishment of mitotic spindle orientation GO:0000226 microtubule cytoskeleton organization GO:0000819 sister chromatid segregation GO:0001764 neuron migration GO:0007018 microtubule-based movement GO:0007020 microtubule nucleation GO:0007059 chromosome segregation GO:0007062 sister chromatid cohesion GO:0007067 mitotic nuclear division GO:0007098 centrosome cycle GO:0007100 mitotic centrosome separation GO:0007163 establishment or maintenance of cell polarity GO:0007405 neuroblast proliferation GO:0010970 transport along microtubule GO:0021537 telencephalon development GO:0021543 pallium development GO:0021987 cerebral cortex development GO:0030010 establishment of cell polarity GO:0030705 cytoskeleton-dependent intracellular transport GO:0030900 forebrain development GO:0031023 microtubule organizing center organization GO:0031109 microtubule polymerization or depolymerization GO:0040001 establishment of mitotic spindle localization GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044839 cell cycle G2/M phase transition GO:0046785 microtubule polymerization GO:0047496 vesicle transport along microtubule GO:0050000 chromosome localization GO:0051258 protein polymerization GO:0051293 establishment of spindle localization GO:0051294 establishment of spindle orientation GO:0051297 centrosome organization GO:0051298 centrosome duplication GO:0051299 centrosome separation GO:0051303 establishment of chromosome localization GO:0051640 organelle localization GO:0051642 centrosome localization GO:0051648 vesicle localization GO:0051650 establishment of vesicle localization GO:0051653 spindle localization GO:0051656 establishment of organelle localization GO:0061351 neural precursor cell proliferation GO:0072089 stem cell proliferation GO:0072384 organelle transport along microtubule GO:0098813 nuclear chromosome segregation GO:0099518 vesicle cytoskeletal trafficking GO:2000574 regulation of microtubule motor activity
Molecular Function	GO:0008017 microtubule binding GO:0015631 tubulin binding
Cellular Component	GO:0000775 chromosome, centromeric region GO:0000776 kinetochore GO:0000777 condensed chromosome kinetochore GO:0000779 condensed chromosome, centromeric region GO:0000793 condensed chromosome GO:0000922 spindle pole GO:0005813 centrosome GO:0005819 spindle GO:0005871 kinesin complex GO:0005874 microtubule GO:0005875 microtubule associated complex GO:0031616 spindle pole centrosome GO:0032153 cell division site GO:0032154 cleavage furrow GO:0032155 cell division site part GO:0097610 cell surface furrow GO:0098687 chromosomal region

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-8854518: AURKA Activation by TPX2 R-HSA-5620912: Anchoring of the basal body to the plasma membrane R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-380287: Centrosome maturation R-HSA-5617833: Cilium Assembly R-HSA-69275: G2/M Transition R-HSA-380259: Loss of Nlp from mitotic centrosomes R-HSA-380284: Loss of proteins required for interphase microtubule organization from the centrosome R-HSA-68886: M Phase R-HSA-68882: Mitotic Anaphase R-HSA-453274: Mitotic G2-G2/M phases R-HSA-2555396: Mitotic Metaphase and Anaphase R-HSA-68877: Mitotic Prometaphase R-HSA-1852241: Organelle biogenesis and maintenance R-HSA-195258: RHO GTPase Effectors R-HSA-5663220: RHO GTPases Activate Formins R-HSA-380270: Recruitment of mitotic centrosome proteins and complexes R-HSA-2565942: Regulation of PLK1 Activity at G2/M Transition R-HSA-2500257: Resolution of Sister Chromatid Cohesion R-HSA-2467813: Separation of Sister Chromatids R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-8854518: AURKA Activation by TPX2
R-HSA-5620912: Anchoring of the basal body to the plasma membrane
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-380287: Centrosome maturation
R-HSA-5617833: Cilium Assembly
R-HSA-69275: G2/M Transition
R-HSA-380259: Loss of Nlp from mitotic centrosomes
R-HSA-380284: Loss of proteins required for interphase microtubule organization from the centrosome
R-HSA-68886: M Phase
R-HSA-68882: Mitotic Anaphase
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-380270: Recruitment of mitotic centrosome proteins and complexes
R-HSA-2565942: Regulation of PLK1 Activity at G2/M Transition
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NDE1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NDE1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NDE1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.424	0.149
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.562	0.768
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.34	0.768
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.111	0.711
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.21	0.922
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.012	0.997
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.196	0.522
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.293	0.834
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.036	0.981
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.728	0.52
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.075	0.96
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.109	0.138

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NDE1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	0	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	0	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NDE1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NDE1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NDE1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NDE1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NDE1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NDE1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NDE1
Name	nudE neurodevelopment protein 1
Aliases	nudE; FLJ20101; NDE; nudE nuclear distribution gene E homolog 1 (A. nidulans); nudE nuclear distribution E h ......
Chromosomal Location	16p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NDE1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NDE1